We would love to hear your thoughts about our site and services, please take our survey here.
Aberforth Partners LLP have gone from 5.78% to zero.
Maybe shorts closing has caused this price rise.
Thankful I do not and never have held.
Only for those with balls of steel I think.
Merck has dropped out of the CoVid vaccine race.
Merck and PDSB are using Versamune in combination with Keytruda (PDS0101)
Merck may also be aware of PDSBs CoVid vaccine candidate and the pre clinical data from Brazil.
Named Versamune-CoV-2FC, the vaccine has just received support from the National Health Surveillance Agency (Anvisa) to submit the documentation of the non-clinical trials for initial analysis, and subsequent submission of the protocol for the clinical trial.
Just out, Covid Vaccine finishing Animal Trials
https://g1.globo.com/sp/ribeirao-preto-franca/noticia/2021/01/21/startup-de-ribeirao-preto-quer-testar-vacina-contra-covid-19-em-maio-rotina-de-producao-esta-acelerada-diz-ceo.ghtml
I suspect large numbers of private investors are already gone and easy to see why.
Previous history reaching a peak of around £20 in mid 2015
( £2 before recent share consolidation) to recent lows of just over 40 pence.
I reckon fewer holders with larger holdings looking forward to significant gains.
They used to pay two Dividends a year.
It is a sign of their recovery that they have reinstated a Dividend.
I would anticipate a significant uplift in their next Dividend.
Song are almost £1.5 billion Market Cap.
So 100 times the vlaue of One Media and as you say no TCAT
Here we are almost 5 months since the Placing.
Low Market Cap, sp much lower than the Placing and in
the period some news on other holdings, but most on PDS Biotechnology.
Still some exiting at these low prices.
I can't help thinking we will soon receive news on at least one investment and
people will be scrambling to buy in.
With most weak holders gone and only 6 million shares in retail hands, possibly less
it indicates what is likely to happen.
The business model is similar to Braveheart, which I have been holding for several years.
In that time there were weeks when Braveheart was not traded, with a wide spread, I sat on
a loss most of the time.
Last year was entirely different and very profitable for me as a Braveheart investor.
I fully expect to repeat that with NSCI, as it appears the majority of private investors
find it difficult to deal with loss and holding in for any length of time in that situation.
https://www.pdsbiotech.com/images/pdf/presentation/2021/PDSB_Corporate_Overview_-_Jan_2021_FINAL.pdf
I do not believe Schroders sold any shares.
See RNS dated 5th August, which states admission of the Placing shares
was 25th August.
Schroders did not participate in the Placing and the resultant Dilution reduced
their percentage holding by the percentage notified today.
The drop was when they went ex dividend on 11th December.
Who knows what they will do on 6th January when the Dividend is paid.
It is possible some very happy Braveheart shareholders may add to their holdings
knowing news due at the end of January.
Suggestion that operators with deep pockets have been suppressing news
and sp with regard to PDSB.
Not sure of the accuracy, but we shall soon see.
If true we will see PDSB move up sharply and unlike previously, stay there.
As most will know NetScientific have a 5.75% holding in Nasdaq listed PDS Biotech (PDSB)
The last update was on 11th November in relation to their Vaccine collaboration with Farmacore
in Brazil.
Attached is a report published today reporting on research results to date.
mdpi.com/2076-393X/8/4/771/htm
Read Section 2.8. Immunization and Challenge Study in BALB/c Mice
carefully and you will see PDS specifically mentioned.
It would appear, on results to date, they may move to in human trials early
next year.
My thanks to a keen eyed investor on another forum.
You say "Take note of the market, and what it thinks as it's rarely wrong"
I will direct you to RUA - even after a recent steady rise the Market has it very
wrong price wise. It is significantly undervalued.
Earlier this year I was buying Hemo at just over 1 pence and again the Market
was undervaluing it.
Lets see what transpires over the next six months.
Valid points have been raised both positive and negative.
In an ideal world no Company would go down this route.
However what stands out to me is the size of the agreement, significantly
more than the current Market Cap and the scale of Hemogenyx ambitions.
Happy to hold what I have and buckle up for a wild ride.